Lysophosphatidic acid (LPA) is a growth factor-like mediator and a ligand for multiple GPCR. The LPA 2 GPCR mediates antiapoptotic and mucosal barrier-protective effects in the gut. We synthesized sulfamoyl benzoic acid (SBA) analogues that are the first specific agonists of LPA 2 , some with subnanomolar activity. We developed an experimental SAR that is supported and rationalized by computational docking analysis of the SBA compounds into the LPA 2 ligand-binding pocket.
■ INTRODUCTION
Exposure to direct ionizing radiation can result in programmed cell death due to the accompanying DNA damage. Lysophosphatidic acid (LPA, 1-acyl-2-hydroxy-sn-3-glycerophosphate) (1, Figure 1 ) is a growth factor-like lipid mediator with antiapoptotic actions elicited via a set of G protein coupled receptors. LPA GPCR activate antiapoptotic kinase pathways, inhibit apoptosis, promote cell regeneration, and augment DNA repair, altogether. 1−4 Our group has been interested in developing LPA analogues for the attenuation of programmed cell death elicited by radiation and chemotherapeutic agents. 2,5−7 In the course of our studies, we discovered octadecenyl thiophosphate (OTP) (2, Figure 1 ), a synthetic analogue of LPA, which showed strong radioprotective action by rescuing cells from apoptosis and mice irradiated with lethal doses of γ-irradiation. 7 Although OTP is highly effective in protecting animals from radiation injury, it activates multiple LPA GPCRs, including LPA 1 that has been linked to cause apoptosis via anoikis. 8, 9 Recently, our group identified novel nonlipid compounds that are selective, although not specific, agonists of LPA 2 and also inhibit LPA 3 . 10 Among these nonlipid compounds, GRI977143 (3, Figure 1 ), although much less potent than LPA, nevertheless showed antiapoptotic efficacy in cell-based models of apoptosis and it was modestly efficacious against radiation-induced apoptosis in mice suffering from the acute hematopoietic radiation syndrome. 10 In continuation of this line of research, we designed and synthesized sulfamoyl benzoic acid (SBA) analogues of 3 by isoteric replacement of −S− group with −NH-SO 2 using a medicinal chemistry approach guided by computational modeling. 11, 12 All 14 new SBA analogues were tested for agonist and antagonist activity at the LPA 1/2/3/4/5 GPCR. We found several nonlipid specific agonist of LPA 2 , one of which is 5-chloro-2-(N-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)sulfamoyl)benzoic acid (11d) (Scheme 4), with picomolar activity (EC 50 = 5.06 × 10 −3 ± 3.73 × 10 −3 nM vs LPA 18:1; EC 50 = 1.40 ± 0.51 nM) ( Figure 2 ).
■ RESULTS AND DISCUSSION
The synthesis of new novel SBA analogues, compounds 4−6, 7a−b, 8a−c, 9−10, and 11a−d, is outlined in Schemes 1−4, respectively.
2-(Bromoalkyl)benzo[de]isoquinoline-1,3-dione (15a−c) was obtained in high yield following a similar approach of that already reported procedure. 13 Compound 15a−c was reacted with 2-sulfamoylbenzoic acid ethyl ester (16) using K 2 CO 3 in DMF to get compounds 4−6 in moderate yield (Scheme 1). 2-[4-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)butylsulfamoyl]benzoic acid (7a) and 2-(N-(4-(2,3-dioxoindolin-1-yl)butyl)sulfamoyl)benzoic acid (7b) were synthesized by the reaction of commercially available 2-(3-bromobutyl)isoindole-1,3-dione (17) and 1-(4-bromobutyl)indoline-2,3dione (19) (which was prepared from 14b and isatin 18) using 16, respectively (Scheme 2).
2-(N-(4-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)sulfamoyl)-substituted benzoic acid (8a−c) was accomplished by the reaction of 15b and substituted benzo[d]isothiazol-3(2H)-one-1,1-dioxides (20a−c) in the presence of K 2 CO 3 and DMF under reflux conditions in moderate yield. (9) , which was then treated with aqueous 1N NaOH to procure the desired compound 2-(N-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)sulfamoyl)terephthalic acid (10) (Scheme 3).
N-Butylamino-1,8-naphthalimide (22) 14 was coupled with substituted sulfonyl chloride 23a−e using triethylamine in THF to furnish corresponding ester derivatives (12a−e). Upon treatment of compound 12b−c with LiOH in THF−water (1:1) and compound 12d−e with K 2 CO 3 in DMF afforded the final acid derivatives 11a−b and 11c−d, respectively, in moderate to quantitative yield (Scheme 4).
LPA receptor activation leads to a transient mobilization of Ca 2+ that can be quantified by measuring the fluorescence of the indicator dye Fura-2AM. All compounds were tested using cell lines established previously to overexpress a single LPA GPCR subtype. 10, 11 For the human LPA 1 , LPA 2 , and LPA 3 GPCR, we used mouse embryonic fibroblasts (MEF) derived from LPA 1 xLPA 2 double knockout mice (DKO) that lack endogenous LPA 3 expression and do not respond to LPA with Ca 2+ transients (for assay details and the LPA 4 and LPA 5 cells, see the Supporting Information). The compounds were evaluated for agonist and antagonist activity ( Table 1) . For agonists compounds, their dose−response was compared to that elicited by LPA 18:1 using a FLEX-Station III robotic plate reader as described in our previous publication. 10 We embarked on a scaffold derivatization approach steered by structure-based pharmacophore design. Studies were initiated with GRI977143 (3) as a template scaffold with the aim of achieving LPA 2 subtype agonist specificity by eliminating LPA 3 antagonist activity and improving its potency through molecular modifications. Our approach was to prioritize the scaffold variants through several iterative steps. Ten different scaffolds based on 3 were flexibly docked into the LPA 2 homology model 10, 11 and first ranked by lowest energy docked score. Each scaffold was then ranked based on the protein− ligand interaction fingerprint, and a final ranking was constructed based on visual inspection of pharmacophore match. Using this strategy in combination with perceived ease of synthesis, 2-(N-(3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)sulfamoyl)benzoic acid (4) was selected. Compound 4 had virtually identical overlay with respect to the shape of 3 where sulfur was replaced by a sulfamoyl moiety (Figure 1 ). Molecular modeling studies comparing compounds 3 and 4 suggested that the improved potency and selectivity of compound 4 was attributed to the increased binding affinity of compound 4 (−8.53 kcal/mol) compared to compound 3 (−7.94 kcal/mol). While both compounds can adopt similar conformations in the binding pocket, compound 4 has a higher conformation strain at 12.39 kcal/mol than compound 3 at 4.32 kcal/mol ( Figure 3A) . The pharmacological characterization of compound 4 at LPA 2 showed that, in spite of its low potency (EC 50 LPA 2 ∼ 2 μM), it was a specific agonist of LPA 2 without activating or inhibiting LPA 1/3/4/5 receptors. Of note is that, unlike GRI977143, compound 4 lacked LPA 3 antagonist activity up to 10 μM, the highest concentration tested (Table  1) . Therefore, this scaffold 4 was deemed an optimal template for guiding lead optimization medicinal chemistry. Medicinal chemistry focused SAR to increase the potency by synthesizing derivatives of compound 4 by modifying at three target regions: the head group, chain linker, and tail group (Figure 1) . We docked and evaluated the chain linker of compound 4 by increasing the carbon numbers to four carbon (compound 5) and five carbon (compound 6) linkers, which are similar in length to the high-potency natural ligand LPA 18:1 of the LPA 2 . Computational models of the docked linker analogues predicted the overall length of compounds of these analogues at 14, 15, and 16 Å, respectively. Pharmacological characterization of these three compounds 4, 5, and 6 showed that compound 5 transfected with the human LPA receptor orthologue (in parentheses) or transduced with appropriate empty vector. EC 50 concentration is given in μM for dose−response curves covering the 0.0001 nM to 10 μM range. For determination of antagonist action, dose−response curves were generated using an ∼E max50 concentration of LPA 18:1 for any given LPA receptor subtype, and the ligand was coapplied in concentrations ranging from 30 nM to 10 μM. Means represent the mean values of three assays. with a four carbon linker had the highest potency, lowering the EC 50 value of the compound from the micromolar to the nanomolar range. Thus, the optimal length of these analogues is at or near 15 Å that is the same as of LPA 18:1 (Scheme 1 and Table 1 ). In continuation of our SAR, we explored the modifications of compound 4 by keeping the linker length fixed at four carbons. We replaced the 1H-benzo[de]isoquinolyl-1,3(2H)-dione tail group with isoindolyl-1,3-dione (17) or indolyl-2,3-dione (18) to obtain compounds 7a and 7b, respectively. These two changes abolished the activation of LPA 2 up to 10 μM, the highest concentration tested. These tail groups are predicted to occupy a highly hydrophobic region in the LPA binding pocket. Modeling of the tail groups of compounds 7a and 7b in the LPA 2 binding pocket predicts several missing π−π interactions (Supporting Information Figure 1 ), which is the reason for their lack of activity. In our final SAR modifications, we modified the phenyl head group of compound 4. We replaced the hydrogen, which is para to the carboxy group in compound 4 by an electron donating methoxy group or withdrawing bromo group yielded compounds 8a and 8b, respectively. Compound 8a showed very weak agonist activity, whereas compound 8b was more potent than compound 4. We also introduced dicarboxy groups on the head group to improve the potency because previous analysis of intramolecular pH predicted that two negative charges of the LPA phosphate interact with the receptor. 10 During the synthesis of the dicarboxy analogue (compound 10), we obtained a cyclized intermediate compound 9, which was further hydrolyzed to dicarboxy analogue 10. Compound 10 was considerably less potent than the compound 9. Next we turned our attention to introduce the electron withdrawing groups. Fluoro, chloro, and bromo substitutions in meta position to the carboxy group of compound 4 produced compounds 11c, 11d, and 8c, respectively. Among these three analogues, compound 11d exhibited picomolar activity (EC 50 (nM): 5.06 × 10 −3 ± 3.73 × 10 −3 vs LPA 18:1; 1.40 ± 0.51), whereas compounds 11c and 8c showed 0.15 ± 0.02 nM and 60.90 ± 9.39 nM, respectively. Molecular docking simulations revealed that the addition of halogens at the para position would lead to compounds with a conformation strain similar to compound 3. Compound 11d is predicted to share approximately the same distance in critical interactions with R3.28 and Q3.29 as compounds 3 and 4, however, compound 11d binding affinity is −9.21 kcal/mol and conformation strain is 6.50 ( Figure 3B ). To complete our SAR studies, finally we prepared additional two compounds where we changed the position of carboxy group on the head group of phenyl ring of compound 4 from ortho to meta (compound 11a) and para (compound 11b) positions that abolished the activity at LPA 2 . The corresponding methyl carboxy esters of compounds 5 and 11a−d (compound 12a−e) were also inactive at activating LPA 2 up to 10 μM, the highest concentration tested.
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■ CONCLUSION
Here we designed and synthesized new SBA analogues using a structure-based pharmacophore. Starting from our active scaffold 4, the detailed structure−activity relationship profile was established to understand the effect of particular substituents on head and tail groups along with carbon linker. We concluded that three important structural requirements are critical to have potent and specific LPA 2 agonistic activity; (i) four carbon chain linker, (ii) keeping the same tail group 1Hbenzo[de]isoquinolyl-1,3(2H)-dione, and (iii) introducing the electron withdrawing group such as chloro meta to the carboxy group of compound 4. This approach yielded compound 11d, which is the first nonlipid specific agonist of LPA 2 with picomolar affinity.
■ EXPERIMENTAL SECTION
Chemistry. All compounds were analyzed by 1 H NMR, 13 C NMR, MASS, and HRMS. The purity of final compounds was ≥95% as measured by HPLC. Full experimental procedures can be found in the Supporting Information.
Analytical Data for Compound 11d. Yield 53%. 1 13 Experimental details of chemical synthesis, computational and biological tests. This material is available free of charge via the Internet at http://pubs.acs.org.
